Melisa Wong Points Out Potential Age Bias in Active Treatment of Lung Cancer
Melisa Wong lays out the findings of a study she did looking at the age of patients with recurrent lung cancer and the likelihood they were to receive active treatment.
Melisa Wong, MD, of the University of California, San Francisco, lays out the findings of a study she did looking at the age of patients with recurrent lung cancer and the likelihood they were to receive active treatment.
The study found that for every 10-year increase in age, a patient was 25% less likely to receive active care—a patient aged 70 years was 25% more likely than one aged 80 to receive active treatment for their cancer. She suggests that age bias, among other reasons, could be responsible for this gap.
FDA Approves Amivantamab-Chemo Combo for Advanced NSCLC
September 19th 2024The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR TKI.
